• Avalo Therapeutics CFO Christopher Ryan Sullivan sold 12,394 common shares at USD 16.33 on Sep. 16, 2026.
• Sale followed the exercise of stock options for 12,394 shares at USD 9.88.
• Directly held common shares fell to 39,900.
• Directly held stock options rose to 83,848.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001810417-26-000023), on September 18, 2026, and is solely responsible for the information contained therein.